Performance of a time-resolved fluorescence immunoassay for measuring varicella-zoster virus immunoglobulin G levels in adults and comparison with commercial enzyme immunoassays and Merck glycoprotein enzyme immunoassay.
Highly sensitive and specific, quantitative assays are needed to detect varicella-zoster virus (VZV) immunoglobulin G in human sera, particularly for determining immune status and response following vaccination. A time-resolved fluorescence immunoassay (TRFIA) has been developed, and its performance was compared to that of two commercial enzyme immunoassays (EIAs) and Merck glycoprotein EIA (gpEIA). The TRFIA had equivalent sensitivity (97.8%) and high specificity (93.5%) in relation to gpEIA. A commercial (Behring) EIA compared favorably with TRFIA in terms of sensitivity (98.4%) but had lower specificity (80.7%). Another commercial EIA (Diamedix) had high specificity (97.1%) but low sensitivity (76.4%) compared to TRFIA if equivocal test results were treated as negative for VZV antibody. A novel feature of the TRFIA was that the cutoff was generated using population mixture modeling and was expressed in mIU/ml, as the assay was calibrated using the British standard VZV antibody.
Maple
P A C
PA
Virus Reference Department, Health Protection Agency Centre for Infections, Colindale, London NW9 5HT, United Kingdom. chris.maple@hpa.org.uk
Gray
J
J
Breuer
J
J
Kafatos
G
G
Parker
S
S
Brown
D
D
D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D015200:Fluoroimmunoassay / Q000379:methods* / Q000706:statistics & numerical data; D014645:Herpesvirus 3, Human / Q000276:immunology*; D006801:Humans; D007124:Immunoenzyme Techniques / Q000379:methods / Q000706:statistics & numerical data; D007074:Immunoglobulin G / Q000097:blood*; D012680:Sensitivity and Specificity
D000914:Antibodies, Viral; D007074:Immunoglobulin G